Genesis Clinical Research (St. Joseph's Hospital)
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sadanandan, Saihari
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Recruiting
N/A
3100
Europe, US, RoW
Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent
Medstar Health Research Institute
Atherosclerosis
04/27
08/27
Navarro, Jesus
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD
Active, not recruiting
3
806
Europe, Canada, Japan, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD
Pulmonary Disease, Chronic Obstructive
08/24
08/24
REGEN-006, NCT05099770: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Recruiting
3
685
Europe, Canada, US, RoW
Renal Autologous Cell Therapy (REACT), Sham Comparator
Prokidney, Iqvia Pty Ltd, PPD
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
02/27
02/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
NCT04939116 / 2021-006579-41: Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Recruiting
2
100
US, RoW
ANG-3070, Placebo
Angion Biomedica Corp, Angion Biomedica Corp.
Glomerular Disease, Proteinuria
07/23
08/23
NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

Recruiting
2
60
US
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Mineralys Therapeutics Inc.
Chronic Kidney Disease
10/24
01/25
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Recruiting
2
384
US
RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo
Reata, a wholly owned subsidiary of Biogen
Diabetic Peripheral Neuropathic Pain
08/26
08/26
NCT04629170: Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

Completed
1
77
US
SYNB8802, Placebo
Synlogic
Healthy, Enteric Hyperoxaluria
01/23
01/23

Download Options